Prenetics Reports Record Q1 Results and Raises Full-Year 2026 Guidance

In a move reflecting a successful strategic pivot toward health sciences, Prenetics Global Limited announced record financial results for the first quarter of 2026. The company reported total revenue of $36.0 million, with the IM8 brand contributing a dominant $33.8 million to the top line. Consequently, the company raised its full-year 2026 revenue guidance for IM8 to a range of $190 million to $210 million, while Major Drilling also reported record annual revenue for its fiscal year ended April 30.

This growth comes as biotechnology and health science firms face mixed sector pressures, yet Prenetics' focus on consumer health has provided a distinct competitive edge. In comparison to specialized industrial peers, Major Drilling's results highlighted robust demand within the mining sector, consistent with global commodity price stability per market data. The company's balance sheet was further streamlined following the divestment of non-core digital assets to prioritize organic growth in health diagnostics.

Traders are currently monitoring PRE stock, which closed at $21.63 on June 12, 2026, after trading between a low of $20.34 and a high of $22.22 per market data. Looking ahead at the economic calendar, investors are awaiting Chinese inflation data and Eurozone industrial production figures in the coming days to gauge broader market sentiment. The upwardly revised revenue guidance remains the primary catalyst for the stock in the near term.